Neptune Technologies & Bioressources Inc. Partners With JAMIESON LABORATORIES
Monday, January 31 2005

Neptune Technologies & Bioressources Inc. Partners
With JAMIESON LABORATORIES

MONTREAL, Jan. 31, 2005 /CNW Telbec/ - Neptune Technologies & Bioressources Inc. proudly announces that Jamieson Laboratories, Canada's largest manufacturer and distributor of advanced natural health-care products, launches two new products with Neptune Krill Oil, NKO™.

The primary product, to be launched in the United States, is an anti aging complex, sold under the Promedis division, the first ever to have the proprietary NKO™ formulation in such a complex. "We will aggressively invest to get our product with NKO™ recognized by anti aging dermatology practitioners for its multiple benefits for human health and well-being.
Everyone will benefit, Neptune, Jamieson, Physicians and especially the consumer", says Frank Lucchetta, Senior Vice President at Jamieson Laboratories. The second NKO™ product, Omega-3 Complex, now launched in Canada, is one of the new formulations, distributed exclusively by the Quest brand division available in premium natural product health food stores.

"The Jamieson Laboratories deal is an important one; Neptune will benefit from Jamieson's extensive knowledge, credibility and sales force, in the market. The Jamieson team has done an incredible marketing plan for the launch of their two new products with NKO™", said Bernard Giguère, Vice President, Sales and Marketing, at Neptune Technologies & Bioressources Inc. "Jamieson is a world leader in the vitamin and nutrition industry, exporting to over 30 countries including the USA, China, Japan, Hong Kong, Korea, Singapore and many Middle Eastern nations; more to come for Neptune", added Mr. Giguère.

Neptune Technologies & Bioressources Inc. develops and exploits marine biomasses with its patented extraction process (Neptune OceanExtract™) utilizing marine biomasses, such as krill, and due to its technologies, Neptune Technologies & Bioressources Inc., is strategically well positioned in the $182 billion global nutrition market (Nutrition Business Journal, Oct/Nov 2004) based on the health and wellness concepts, markets in which natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research.

Neptune Technologies & Bioressources Inc. is listed on the following Stock Exchange Market TSX-V Venture Exchange under the ticker symbol NTB.V, Berlin Exchange under the ticker symbol NTB.BE and the U.S Pink Sheets Exchange under the ticker symbol NPTZF.PK.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the adequacy or accuracy of this press release.
Neptune Technologies and Acasti Pharma Contact:
Neptune Technologies & Bioressources Inc.
Acasti Pharma Inc.
Toni Rinow, Ph.D., MBA
Corporate Development & Investor Relations
(450) 687-2262
This e-mail address is being protected from spambots, you need JavaScript enabled to view it
# # #
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.
< Prev   Next >
 
back to press releases list

We communicate

NTB (TSX) CAN$ 1.93 +0.03
NEPT (NASDAQ) US$ 1.898 +0.068
 

press releases

Neptune subsidiary Acasti reports superior effect of Drug Candidate CaPre over Lovaza
 
Neptune Appoints IR firm for the US
 

Investor Relations Contact NEPTUNE TECHNOLOGIES & BIORESSOURCES